Studies | EBMT

Top

Study type

Disease

Group

Type of transplant / Cell therapy

Text

Language

Survey on the use of SGLT2 inhibitors in cell therapy including autologous and allogeneic hematopoietic stem cell transplantation and CART cell therapy

Toutes les maladies

Transplant Complications Working Party (TCWP)

Type de traitement

Investigateur principal

Christian Schultze-Florey

How risky is a second allo? A retrospective analysis of treatment-related mortality in patients receiving allogeneic stem cell transplantation for the second time

Études rétrospectives

Toutes les maladies

Transplant Complications Working Party (TCWP)

Type de traitement

Investigateur principal

Daratumumab for PRCA after alloSCT

Retrospective Studies

Complications: non-infectious

Transplant Complications Working Party (TCWP)

Type de traitement

Investigateur principal

Outcomes of PT-CY in elderly AML/MDS

Retrospective Studies

Transplant Complications Working Party (TCWP)

Type de traitement

Investigateur principal

Maria Queralt Salas

Immune Checkpoint Inhibitors for solid tumors after allogeneic stem cell transplantation

Retrospective Studies

Transplant Complications Working Party (TCWP)

Type de traitement

Investigateur principal

Pre-transplantation diabetes and obesity and acute graft-versus-host disease after allogeneic hematopoietic cell transplantation

Retrospective Studies

Complications: GvHD

Transplant Complications Working Party (TCWP)

Type de traitement

Investigateur principal

Lars Klingen Gjaerde

Chronic GVHD over time - a multicenter retrospective study

Retrospective Studies

Transplant Complications Working Party (TCWP)

Type de traitement

Investigateur principal

Steroid-free first line treatment of moderate and severe chronic GVHD - restrospective study

Retrospective Studies

Transplant Complications Working Party (TCWP)

Type de traitement

Investigateur principal

Effects of donor clonal hematopoiesis in unrelated HSCT

Retrospective Studies

Transplant Complications Working Party (TCWP)

Type de traitement

Investigateur principal

F. Damm & J. Schetelig

Machine learning approach to estimate toxicity-related mortality following allogeneic HSCT

Retrospective Studies

Transplant Complications Working Party (TCWP)

Type de traitement

Investigateur principal

Alberto Mussetti

Lung GvHD - Review of current practices

Transplant Complications Working Party (TCWP)

Type de traitement

Investigateur principal

John Murray; Saskia Bos

EBMT patient engagement taskforce (PRO)

Closed Survey/Study

Transplant Complications Working Party (TCWP)

Type de traitement

Investigateur principal

Helene Schoemans